Market fit Target biotech and gene therapy companies seeking big DNA delivery capabilities and genome writing solutions, highlighting Replay’s synHSV technology and high payload platform as a means to expand therapeutic applications beyond traditional vectors.

Strategic partnerships Leverage Replay’s hub-and-spoke model to offer technology development services to product-focused firms, presenting co-development and licensing opportunities for therapeutic programs that require advanced genome writing and delivery platforms.

Portfolio synergies Engage the four gene therapy product companies already leveraging Replay’s synHSV to identify cross-sell or up-sell opportunities for increased payload, improved immunogenicity profiles, or streamlined development timelines.

Funding readiness Position Replay as a platform enabler for funded programs by aligning with investor interest in genome writing and AI-enabled optimization, using its current funding and revenue scale to validate a scalable, multi-product strategy.

Emerging markets Explore expansion into dermatology, ophthalmology, neurology, and muscle disease spaces where big DNA treatments could address unmet needs, leveraging existing therapeutic focus areas and demonstrated platform capabilities.